Chris Dufton

Chris Dufton serves as the Vice President of Clinical Development and Operations at Edgewise Therapeutics, where responsibilities include leading development operations for a cardiology program focused on cardiac myosin modulators. Prior to this role, Chris held the position of Senior Vice President of Clinical Development at InCarda Therapeutics, specializing in novel inhalation treatments for cardiovascular conditions. Chris also contributed to ARCA biopharma as Vice President of Clinical Development, where the focus was on precision medicine in cardiovascular therapies. As a consultant at Rubicon Sciences LLC, Chris provided strategic insights for clinical, regulatory, and business development in the biotech industry. Chris began a career in clinical research at Gilead Sciences Inc, leading the post-launch development of ambrisentan. Academic credentials include a PhD in Molecular, Cellular, and Developmental Biology from the University of Colorado Boulder and graduate studies in Immunology and Pharmacology at the University of Colorado School of Medicine.